Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

Barclays analyst Luke Sergott has maintained an Overweight rating on Guardant Health (NASDAQ: GH) and increased the price target from $200 to $220. This adjustment reflects a positive outlook on the company's performance.